HEALTH

Botox approved for migraines

BY Alaric DeArment

SILVER SPRING, Md. A popular beauty treatment has won approval as a medical treatment as well.

 

The Food and Drug Administration announced Friday the approval of Allergan’s Botox (onabotulinumtoxinA) for preventing headaches in adult patients with chronic migraine.

 

 

“Chronic migraine is one of the most disabling forms of headache,” FDA division of neurology products director Russell Katz said. “Patients with chronic migraine experience a headache more than 14 days of the month. This condition can greatly affect family, work and social life, so it’s important to have a variety of effective treatments available.”

 

keyboard_arrow_downCOMMENTS

Leave a Reply

D.CALABRESE says:
Sep-02-2013 09:43 pm

Can you please share what are the chemicals or ingredients used with this botox treatment? Surely they have included something on it that will help cure and prevent chronic migraine. Also, please include what are the suggested ages for a person to have this treatment. I’d also ask my friend from colleyville botox about it. Wish to get the important information from this treatment.

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

PharmaLink gets orphan drug designation for Nefecon

BY Alaric DeArment

STOCKHOLM The Food and Drug Administration has given orphan drug designation to a treatment for a rare kidney disease under mid-stage clinical development by privately owned Swedish drug maker PharmaLink, the company said.

 

The FDA granted the designation to Nefecon (PL-56), a treatment for IgA nephropathy, also known as Berger’s disease, a disorder that leads to end-stage kidney disease. The FDA gives orphan drug designation to incentivize development of treatments for rare and serious disorders.

 

 

“Today’s news marks a significant milestone for PharmaLink and increases the commercial value of Nefecon as it moves toward the marketplace,” PharmaLink managing director Johan Haggblad said. “We believe this product candidate has great potential in treating IgA nephropathy.”

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Medco: Poor adherence may cause lack of response to medication

BY Alaric DeArment

BOSTON When a patient isn’t showing a response to a medication, a common tactic the doctor might use is to increase the dosage. According to a new study, however, the ineffectiveness might be happening because the patient isn’t properly taking the medication.

The Medco Research Institute, the research arm of pharmacy benefit manager Medco Health Solutions, found that nearly one-third of patients given increased dosages of antidepressants were not regularly taking their original prescriptions. Data from the study recently were presented at the American Psychiatric Association’s 62nd Institute on Psychiatric Services in Boston.

 

Medco said the study showed doctors should monitor a patient’s adherence to their antidepressants before raising the dosage because poor adherence may contribute to disease relapse, thus leading to unnecessary dosage increases.

 

 

“A physician usually increases a dose when a patient is not responding to the current dosage,” Medco Neuroscience Therapeutic Resource Center national practice leader and lead study author David Muzina said. “But the analysis shows that the reason the dose may not be effective is that many patients are not taking their antidepressants as directed.”

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?